Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA (CVXGA50) Intranasal COVID-19 Vaccine in Adults

NCT06742281 is registered in ClinicalTrials.gov with CyanVac LLC as lead sponsor.

NCT NCT06742281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06742281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA (CVXGA50) Intranasal COVID-19 Vaccine in Adults
Lead sponsor
CyanVac LLC
Phase
Phase 2
Overall status
Completed
Start date
December 5, 2024
Completion date
June 15, 2026
Enrollment
432 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19